Aluna

Aluna's core offering is an AI-enabled platform that includes a portable, FDA-cleared spirometer that pairs with a smartphone app via Bluetooth. This system allows patients, including children aged five and up, to perform daily lung function tests at home, mirroring the spirometry exams conducted in a doctor's office. The pocket-sized device measures key metrics such as FEV1% (Forced Expiratory Volume in 1 second), which are automatically tracked over time. The platform is designed to serve both patients and healthcare providers, including allergists and pulmonologists. By enabling remote patient monitoring, Aluna helps doctors track daily fluctuations in lung function and other patient-reported data to manage conditions proactively and potentially prevent emergency situations.

The business model is centered on its remote patient monitoring (RPM) platform, with revenue generated from the sale of the spirometer device and services eligible for insurance coverage under RPM codes. In January 2023, the company announced it had raised a $15.3 million Series B round, bringing its total funding to $27 million. This followed a period of significant growth, with a 10x increase in patients on its platform year-over-year. The company was acquired by Huma on May 16, 2025. The platform's app is designed to be engaging, particularly for pediatric patients, by gamifying the process of spirometry. Patients can log symptoms, medication use, activity levels, and environmental triggers, providing a comprehensive view of their respiratory health that can be shared with their healthcare provider.